According to the Guidelines for Breast Cancer Diagnosis and Treatment by the China Anti-Cancer Association, patients with hormone receptor-positive, HER2-negative advanced breast cancer, and no evidence of visceral crisis can be treated with endocrine therapy combined with CDK4/6 inhibitors (36). This evidence concerns the gene ERBB2 and breast cancer.